IBRX-042 / ImmunityBio - LARVOL DELTA

QUILT-3.100: IBRX-042 In Participants With HPV-Associated Tumors (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: ImmunityBio, Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2025 ➔ Sep 2027

Enrollment closed • Trial primary completion date • Oncology

IBRX-042 In Subjects With HPV-Associated Tumors (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: ImmunityBio, Inc. | Not yet recruiting ➔ Recruiting | N=18 ➔ 12 | Trial primary completion date: Dec 2024 ➔ Sep 2025

Enrollment change • Enrollment open • Trial primary completion date • Oncology

IBRX-042 In Subjects With HPV-Associated Tumors (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: ImmunityBio, Inc. | Initiation date: Mar 2024 ➔ Jun 2024

Trial initiation date • Oncology

IBRX-042 In Subjects With HPV-Associated Tumors (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: ImmunityBio, Inc. | Initiation date: Aug 2023 ➔ Mar 2024

Trial initiation date • Oncology

IBRX-042 In Subjects With HPV-Associated Tumors (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: ImmunityBio, Inc.

New P1 trial • Oncology